---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-061244"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-05-27T12:10:30+00:00"
generated_at: "2026-05-27T12:15:55.358667+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics announces peer-reviewed publication supporting GX-03's activity in IL-36 inflammatory model

## Summary
- Study in murine dermatitis model showed mean IGA score of 1.44 vs 3.00 for untreated controls (p=0.0003) after 7 days of GX-03.
- No treatment-related adverse effects observed; IL-36 expression confirmed following Staphylococcus aureus exposure.
- Publication in Journal of Dermatological Treatment; first in planned series on GX-03's scientific rationale.
- GX-03 is in Phase 2 for moderate-to-severe atopic dermatitis; topline results expected mid-2026.

## SEC filing metadata
- accession: 0001213900-26-061244
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-05-27T12:10:30+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026061244/0001213900-26-061244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026061244/ea0291866-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-061244
- JSON: https://secwatch.observer/filing/0001213900-26-061244.json
- Plain text: https://secwatch.observer/filing/0001213900-26-061244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.